Non-Muscle Invasive Bladder Cancer (NMIBC) is a common, heterogeneous disease associated with high rates of recurrence that usually requires lifelong surveillance. The cancer is found in the tissue, which lines the inner surface of the bladder wherein the bladder muscle is not involved.
&nbsp;
Approximately 70&ndash;80% patients with newly diagnosed bladder cancer present with a form of non-muscle-invasive bladder cancer (NMIBC), such as non-invasive papillary tumour (pTa), carcinoma in situ (CIS; pTis), or early invasive tumour (non-muscle invasive; pT1). These tumours characteristically recur in 50&ndash;70% of cases, with only approximately 10&ndash;20% of cases progressing to muscle-invasive bladder cancer (MIBC).
&nbsp;
Non-Muscle Invasive Bladder Cancer Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Non-Muscle Invasive Bladder Cancer in 7MM from 2017 to 2030 is segmented as:-&nbsp;
<ul>
<li>Prevalent cases of Bladder Cancer</li>
<li>Diagnosed Prevalent cases of Bladder Cancer</li>
<li>Diagnosed Prevalent cases of NMIBC</li>
<li>Age-specific Diagnosed Prevalence of NMIBC</li>
<li>Tumour (T) stage-specific Diagnosed Prevalence of NMIBC</li>
<li>Grade-specific Diagnosed Prevalence of NMIBC</li>
<li>Risk-specific Diagnosed Prevalence of NMIBC</li>
</ul>
&nbsp;
Non-Muscle Invasive Bladder Cancer Epidemiology&nbsp;
<ul>
<li>The total diagnosed prevalent population of NMIBC in 7MM in 2017 was 533,263</li>
<li>EU5 countries occupied approximately 45.90% of the patient pool amongst 7MM in 2017</li>
</ul>
&nbsp;
<a style="color: #0066cc; background-color: transparent;" href="https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market" target="_blank" rel="noopener noreferrer">Non-Muscle Invasive Bladder Cancer Market</a>
The market size of Non-Muscle Invasive Bladder Cancer in 7MM in 2017 was USD 1,454 Million&nbsp;&nbsp;
&nbsp;
Non-Muscle Invasive Bladder Cancer Market Drivers
<ul>
<li>Imminent Launches</li>
<li>The upsurge in Research and Development</li>
<li>Enriched Understanding</li>
<li>Increased Incidence</li>
</ul>
&nbsp;
Non-Muscle Invasive Bladder Cancer Market Barriers
<ul>
<li>High Cost of Therapy</li>
<li>Expression Heterogeneity</li>
<li>Lack of Approved Therapies</li>
</ul>
&nbsp;
Non-Muscle Invasive Bladder Cancer Emerging Drugs
The emerging&nbsp;drugs of the Non-Muscle Invasive Bladder Cancer market are&nbsp;
<ul>
<li>Vicinium</li>
<li>Adstiladrin (nadofaragene firadenovec/Syn3)</li>
<li>Tecentriq (atezolizumab)</li>
<li>Sasanlimab (PF-06801591) + BCG</li>
<li>Apaziquone</li>
<li>Opdivo (nivolumab)</li>
<li>Imfinzi (durvalumab)</li>
<li>VesiGel (UGN-102/mitomycin gel)</li>
<li>Pemigatinib</li>
<li>CG0070</li>
<li>Erdafitinib</li>
<li>Revlimid (lenalidomide): N-803 (ALT-803)</li>
<li>TLD-1433</li>
<li>Bavencio (avelumab + BCG)</li>
<li>Alpha1H</li>
<li>LiPax</li>
<li>Imfinzi (durvalumab) + S-488210/S-488211</li>
</ul>
And many others.&nbsp;
&nbsp;
Non-Muscle Invasive Bladder Cancer Key Players
The key players in the Non-Muscle Invasive Bladder Cancer market are
<ul>
<li>Sesen Bio</li>
<li>FKD Therapies Oy</li>
<li>Ferring Pharmaceuticals</li>
<li>Hoffmann-La Roche</li>
<li>Pfizer</li>
<li>Spectrum Pharmaceuticals</li>
<li>Bristol-Myers Squibb</li>
<li>AstraZeneca</li>
<li>UroGen Pharma</li>
<li>Incyte Corporation</li>
<li>CG Oncology</li>
<li>Janssen Research &amp; Development</li>
<li>Celgene Corporation</li>
<li>ImmunityBio</li>
<li>Altor Biosciences</li>
<li>Theralase</li>
<li>EMD Serono</li>
<li>Hamlet Pharma</li>
<li>TesoRx Pharma</li>
</ul>
And many others.&nbsp;

Non-muscle Invasive Bladder Cancer Market

Non-muscle Invasive Bladder Cancer Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.